Formula I Anti-HPV Compounds for Recurrence Prevention
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for human papillomavirus (HPV) infections, particularly those causing genital warts and cervical cancer, are inadequate, with no known cure and existing treatments often ineffective in preventing recurrence and having adverse effects during pregnancy.
Innovation Solution
Development of specific compounds, represented by the formula I, which act as antiproliferative, apoptotic, and anti-HPV agents, formulated into pharmaceutical compositions such as gels and ointments for topical application, enhancing bioavailability and stability for effective treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing treatments for HPV infections are used, then some symptomatic relief may be achieved, but they are ineffective in preventing recurrence and have adverse effects during pregnancy
Solution Approach 1:
The patent modifies the chemical structure of existing HPV treatment compounds by changing parameters such as substituting fluorine atoms for hydrogen atoms, replacing hydroxyl groups with methoxy groups, and adjusting molecular weight. These parameter changes result in compounds with improved efficacy in preventing recurrence while reducing adverse effects during pregnancy, as demonstrated by the novel compounds of formula I that show enhanced therapeutic index compared to prior treatments.
Solution Approach 2:
The patent creates composite pharmaceutical compositions that combine the novel compound of formula I with specific excipients and delivery systems. These composite formulations enhance the therapeutic effectiveness while minimizing adverse effects, particularly during pregnancy, by optimizing pharmacokinetic properties and targeted delivery to infected tissues.
2Ease of operation
If topical formulations are used for HPV treatment, then targeted delivery to affected tissues is achieved, but bioavailability and stability are limited
Solution Approach 1:
The patent optimizes physical-chemical parameters of the topical formulation including pH adjustment to enhance stability, incorporation of penetration enhancers to improve bioavailability, and selection of appropriate vehicles (gels, creams, ointments) based on the specific application site. These parameter changes enable effective targeted delivery while overcoming the limitations of poor bioavailability and instability inherent in conventional topical HPV treatments.
Solution Approach 2:
The patent employs intermediary substances such as penetration enhancers, surfactants, and stabilizing agents in the topical formulation. These intermediaries facilitate the delivery of the active compound through the skin barrier to infected tissues while maintaining compound stability, thereby resolving the contradiction between targeted delivery and bioavailability/stability.
Data Source
AI summary
Compounds and compositions of Formula I are described, useful as anti-proliferative agents, and in particular anti-HPV,wherein:Y1A and Y1B are independently Y1;RX1 and RX2 are independently RX;Y1 is ═O, —O(RX), ═S, —N(RX), —N(O)(RX), —N(ORX), —N(O)(ORX), or —N(N(RX) (RX));RX is independently R1, R2, R4, W3, or a protecting group;R1 is independently —H or alkyl of 1 to 18 carbon atoms;R2 is independently R3 or R4 wherein each R4 is independently substituted with 0 to 3 R3 groups or taken together at a carbon atom, two R2 groups form a ring of 3 to 8 carbons and the ring may be substituted with 0 to 3 R3 groups;R3 is R3a, R3b, R3c or R3d, provided that when R3 is bound to a heteroatom, then R3 is R3c or R3d;R3a is —H, —F, —Cl, —Br, —I, —CF3, —CN, N3, —NO2, or —OR4;R3b is ═O, —O(R4), ═S, —N(R4), —N(O)(R4), —N(OR4), —N(O)(OR4), or —N(N(R4) (R4));R3c is —R4, —N(R4)(R4), —SR4, —S(O)R4, —S(O)2R4, —S(O)(OR4), —S(O)2(OR4), —OC(R3b)R4, —OC(R3b)OR4, —OC(R3b)(N(R4)(R4)), —SC(R3b)R4, —SC(R3b)OR4, SC(R3b)(N(R4)(R4)), —N(R4)C(R3b)R4, —N(R4)C(R3b)OR4, N(R4)C(R3b)(N(R4)(R4)), W3 or —R5W3;R3d is —C(R3b)R4, —C(R3b)OR4, —C(R3b)W3, —C(R3b)OW3 or —C(R3b)(N(R4)(R4));R4 is —H, or an alkyl of 1 to 18 carbon atoms, alkenyl of 2 to 18 carbon atoms, or alkynyl of 2 to 18 carbon atoms;R5 is alkylene of 1 to 18 carbon atoms, alkenylene of 2 to 18 carbon atoms, or alkynylene of 2 to 18 carbon atoms;W3 is W4 or W5;W4 is R6, —C(R3b)R6, —C(R3b)W5, —SOM2R6, or —SOM2W5, wherein R6 is R4 wherein each R4 is substituted with 0 to 3 R3 groups;W5 is carbocycle or heterocycle wherein W5 is independently substituted with 0 to 3 R2 groups; andM2 is 0, 1 or 2;and pharmaceutically acceptable salts thereof.